Recursion Pharmaceuticals (RXRX) Net Equity Issued and Repurchased (2020 - 2025)

Recursion Pharmaceuticals' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $133.4 million for Q4 2025.

• Quarterly Net Equity Issued and Repurchased rose 1109.25% year-over-year to $133.4 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $487.8 million (up 47.58% YoY) and the FY2025 annual result came in at $528.9 million, up 76.04% from the prior year.
• Net Equity Issued and Repurchased was $133.4 million for Q4 2025 at Recursion Pharmaceuticals, down from $254.5 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $462.9 million in Q4 2021 and bottomed at $10.9 million in Q1 2024.
• A 4-year average of $129.1 million and a median of $78.1 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased tumbled 85.88% — and 2025, when it soared 1399.65%.
• Recursion Pharmaceuticals' Net Equity Issued and Repurchased stood at $462.9 million in 2021, then tumbled by 83.13% to $78.1 million in 2023, then tumbled by 85.88% to $11.0 million in 2024, then jumped by 1109.25% to $133.4 million in 2025.
• Business Quant data shows RXRX's Net Equity Issued and Repurchased at $133.4 million in Q4 2025, $254.5 million in Q3 2025, and $100.0 million in Q2 2025.